{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T02:00:32Z","timestamp":1788314432459,"version":"build-2803163510"},"reference-count":53,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T00:00:00Z","timestamp":1764028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Science and Technology Project of Xizang Autonomous Region of China","award":["XZ202501JD0007"],"award-info":[{"award-number":["XZ202501JD0007"]}]},{"name":"Special Project of the Central Government in Guidance of Local Science and Technology Development of the Xizang Autonomous Region","award":["XZ202401YD0010"],"award-info":[{"award-number":["XZ202401YD0010"]}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Nutr."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Metabolic dysfunction-associated steatotic liver disease is considered the leading cause of chronic liver disease worldwide. By now, no confirmed medication is accessible for the treatment of MASLD. Previous studies showed the positive effects of microbial therapy, such as probiotics, prebiotics, and synbiotics. The study aims to summarize the results of a meta-analysis of randomized controlled trials and evaluate the impact of microbial therapy (probiotics, prebiotics, and synbiotics) on liver radioactive indicators in patients with MASLD and hopes to bring certain benefits to the adjuvant treatment of MASLD populations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A thorough search of PubMed, Scopus, Web of Science, Embase, and Cochrane Library, from inception up to 4 May 2025, was conducted to find meta-analyses on randomized controlled trials reporting the effects of microbial therapy on patients with MASLD. Meta-analyses surveying the impact of microbial therapy on the degree of liver fat infiltration (DFI), hepatic steatosis (HS), hepatic fibrosis (HF), and liver steatosis measurement (LSM) in the MASLD patients were included in our umbrella review. The final effect size (ES) was estimated, and sensitivity and subgroup analyses were performed to explore heterogeneity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 14 meta-analysis studies were included. The findings demonstrated that microbial therapy could significantly improve hepatic steatosis (measured by ultrasound grading) (HS; OR: 2.612; 95% CI: 1.674, 4.075;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), hepatic fibrosis (HF; ES: -0.274; 95%CI: \u22120.427, \u22120.120;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001), and liver stiffness measurement (LSM; ES: \u22120.550; 95%CI, \u22120.716, \u22120.384;\n                      <jats:italic>p<\/jats:italic>\n                      \u202f&amp;lt;\u202f0.001) in patients with MASLD.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The present study suggests that microbial therapies seem to be a promising therapeutic approach to the improvement of hepatic steatosis, liver fibrosis, and liver stiffness in patients with MASLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic Review Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/PROSPERO\/view\/CRD420251043303<\/jats:ext-link>\n                      , identifier PROSPERO (CRD420251043303).\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fnut.2025.1686937","type":"journal-article","created":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:56:26Z","timestamp":1764078986000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["An umbrella meta-analysis of microbial therapy on hepatic steatosis, fibrosis, and liver stiffness in metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.3389","volume":"12","author":[{"given":"Gvzalnur","family":"Kurban","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangjun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyi","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaokang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guiju","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,25]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.clnu.2025.02.007","article-title":"An umbrella review of meta-analyses on the effects of microbial therapy in metabolic dysfunction-associated steatotic liver disease","volume":"47","author":"Yao","year":"2025","journal-title":"Clin Nutr"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1136\/gutjnl-2023-330595","article-title":"MASLD: a systemic metabolic disorder with cardiovascular and malignant complications","volume":"73","author":"Targher","year":"2024","journal-title":"Gut"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","article-title":"A multisociety Delphi consensus statement on new fatty liver disease nomenclature","volume":"79","author":"Rinella","year":"2023","journal-title":"J Hepatol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"106175","DOI":"10.1016\/j.cct.2020.106175","article-title":"The European NAFLD registry: a real-world longitudinal cohort study of nonalcoholic fatty liver disease","volume":"98","author":"Hardy","year":"2020","journal-title":"Contemp Clin Trials"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1016\/S0140-6736(24)01811-7","article-title":"Steatotic liver disease","volume":"404","author":"Israelsen","year":"2024","journal-title":"Lancet"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1016\/j.ejim.2017.10.020","article-title":"Obesity phenotypes and their paradoxical association with cardiovascular diseases","volume":"48","author":"Vecchi\u00e9","year":"2018","journal-title":"Eur J Intern Med"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.mib.2018.06.003","article-title":"Early life colonization of the human gut: microbes matter everywhere","volume":"44","author":"Korpela","year":"2018","journal-title":"Curr Opin Microbiol"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1007\/s12020-018-1605-5","article-title":"Microbiota and metabolic diseases","volume":"61","author":"Pascale","year":"2018","journal-title":"Endocrine"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1038\/s41586-019-1238-8","article-title":"The integrative human microbiome project","volume":"569","year":"2019","journal-title":"Nature"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.3390\/ijms20020395","article-title":"Gut-liver Axis, gut microbiota, and its modulation in the Management of Liver Diseases: a review of the literature","volume":"20","author":"Milosevic","year":"2019","journal-title":"Int J Mol Sci"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"619","DOI":"10.1038\/s41575-025-01089-1","article-title":"Gut microbiome in metabolic dysfunction-associated steatotic liver disease and associated hepatocellular carcinoma","volume":"22","author":"Lau","year":"2025","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"S94","DOI":"10.3350\/cmh.2024.0811","article-title":"Microbiome-centered therapies for the management of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Saeed","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"111180","DOI":"10.1016\/j.foodres.2022.111180","article-title":"Sequentially fermented dealcoholized apple juice intervenes fatty liver induced by high-fat diets via modulation of intestinal flora and gene pathways","volume":"156","author":"Li","year":"2022","journal-title":"Food Res Int"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.jare.2024.03.004","article-title":"Polyphenols synergistic drugs to ameliorate non-alcoholic fatty liver disease via signal pathway and gut microbiota: a review","volume":"68","author":"Li","year":"2025","journal-title":"J Adv Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1093\/nutrit\/nuy031","article-title":"Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"76","author":"Loman","year":"2018","journal-title":"Nutr Rev"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"2642","DOI":"10.3390\/nu11112642","article-title":"The role of probiotics in nonalcoholic fatty liver disease: a new insight into therapeutic strategies","volume":"11","author":"Meroni","year":"2019","journal-title":"Nutrients"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.3390\/foods10081719","article-title":"Probiotics and prebiotics as a strategy for non-alcoholic fatty liver disease, a narrative review","volume":"10","author":"Castillo","year":"2021","journal-title":"Foods"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"438","DOI":"10.37201\/req\/056.2024","article-title":"Human intestinal microbiome: role in health and disease","volume":"37","author":"Cant\u00f3n","year":"2024","journal-title":"Rev Esp Quimioter"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/s12929-018-0493-6","article-title":"Probiotics, prebiotics and amelioration of diseases","volume":"26","author":"Tsai","year":"2019","journal-title":"J Biomed Sci"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"928","DOI":"10.3390\/ijms17060928","article-title":"Effects of probiotics and synbiotics on obesity, insulin resistance syndrome, type 2 diabetes and non-alcoholic fatty liver disease: a review of human clinical trials","volume":"17","author":"S\u00e1ez-Lara","year":"2016","journal-title":"Int J Mol Sci"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"16206","DOI":"10.1038\/s41598-022-20296-3","article-title":"Probiotics suppress nonalcoholic steatohepatitis and carcinogenesis progression in hepatocyte-specific PTEN knockout mice","volume":"12","author":"Arai","year":"2022","journal-title":"Sci Rep"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"2037","DOI":"10.1007\/s00394-017-1568-y","article-title":"Effect of probiotics and synbiotics consumption on serum concentrations of liver function test enzymes: a systematic review and meta-analysis","volume":"57","author":"Khalesi","year":"2018","journal-title":"Eur J Nutr"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"701","DOI":"10.1111\/j.1365-2036.2006.03042.x","article-title":"Review article: prebiotics in the gastrointestinal tract","volume":"24","author":"Macfarlane","year":"2006","journal-title":"Aliment Pharmacol Ther"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"7577","DOI":"10.1007\/s13197-015-1921-1","article-title":"Probiotics, prebiotics and synbiotics- a review","volume":"52","author":"Pandey","year":"2015","journal-title":"J Food Sci Technol"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1093\/ajcn\/nqz042","article-title":"Gut microbiome-targeted therapies in nonalcoholic fatty liver disease: a systematic review, meta-analysis, and meta-regression","volume":"110","author":"Sharpton","year":"2019","journal-title":"Am J Clin Nutr"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"107398","DOI":"10.1016\/j.phrs.2024.107398","article-title":"The effect of synbiotics on liver enzymes, obesity indices, blood pressure, lipid profile, and inflammation in patients with non-alcoholic fatty liver: a systematic review and meta-analysis of randomized controlled trials","volume":"208","author":"Musazadeh","year":"2024","journal-title":"Pharmacol Res"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"1024678","DOI":"10.3389\/fnut.2022.1024678","article-title":"The effects of supplementation of probiotics, prebiotics, or synbiotics on patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials","volume":"9","author":"Xing","year":"2022","journal-title":"Front Nutr"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"1682","DOI":"10.1111\/jgh.16256","article-title":"Use of probiotics, prebiotics, and synbiotics in non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"38","author":"Rong","year":"2023","journal-title":"J Gastroenterol Hepatol"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"ref31","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1002\/jrsm.1092","article-title":"A tool to assess the quality of a meta-analysis","volume":"4","author":"Higgins","year":"2013","journal-title":"Res Synth Methods"},{"key":"ref32","doi-asserted-by":"publisher","first-page":"j4008","DOI":"10.1136\/bmj.j4008","article-title":"AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both","volume":"358","author":"Shea","year":"2017","journal-title":"BMJ"},{"key":"ref33","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.cell.2016.01.013","article-title":"Are we really vastly outnumbered? Revisiting the ratio of bacterial to host cells in humans","volume":"164","author":"Sender","year":"2016","journal-title":"Cell"},{"key":"ref34","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1007\/s10096-019-03746-1","article-title":"Non-alcoholic fatty liver diseases: from role of gut microbiota to microbial-based therapies","volume":"39","author":"Ebrahimzadeh Leylabadlo","year":"2020","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"ref35","doi-asserted-by":"publisher","first-page":"8805","DOI":"10.3390\/ijms23158805","article-title":"The effects of probiotics, prebiotics and synbiotics in non-alcoholic fat liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH): a systematic review","volume":"23","author":"Carpi","year":"2022","journal-title":"Int J Mol Sci"},{"key":"ref36","doi-asserted-by":"publisher","first-page":"844242","DOI":"10.3389\/fnut.2022.844242","article-title":"Effect of probiotics on liver enzymes in patients with non-alcoholic fatty liver disease: An umbrella of systematic review and Meta-analysis","volume":"9","author":"Musazadeh","year":"2022","journal-title":"Front Nutr"},{"key":"ref37","doi-asserted-by":"publisher","first-page":"101924","DOI":"10.1016\/j.bpg.2024.101924","article-title":"Gut microbiome and metabolic dysfunction-associated steatotic liver disease: pathogenic role and potential for therapeutics","volume":"72","author":"Garcia-Mateo","year":"2024","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"ref38","doi-asserted-by":"publisher","first-page":"59","DOI":"10.4103\/2008-7802.178533","article-title":"The effect of symbiotic supplementation on liver enzymes, C-reactive protein and ultrasound findings in patients with non-alcoholic fatty liver disease: a clinical trial","volume":"7","author":"Asgharian","year":"2016","journal-title":"Int J Prev Med"},{"key":"ref39","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1017\/S0007114517000204","article-title":"Synbiotic supplementation in lean patients with non-alcoholic fatty liver disease: a pilot, randomised, double-blind, placebo-controlled, clinical trial","volume":"117","author":"Mofidi","year":"2017","journal-title":"Br J Nutr"},{"key":"ref40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.2478\/rjim-2024-0004","article-title":"The effects of synbiotics on the liver steatosis, inflammation, and gut microbiome of metabolic dysfunction-associated liver disease patients-randomized trial","volume":"62","author":"Mitrovi\u0107","year":"2024","journal-title":"Rom J Intern Med"},{"key":"ref41","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/nu8070397","article-title":"Beneficial effect of synbiotic supplementation on hepatic steatosis and anthropometric parameters, but not on gut permeability in a population with nonalcoholic steatohepatitis","volume":"8","author":"Ferolla","year":"2016","journal-title":"Nutrients"},{"key":"ref42","doi-asserted-by":"publisher","first-page":"1276","DOI":"10.1093\/jn\/nxy088","article-title":"Daily consumption of Synbiotic yogurt decreases liver steatosis in patients with nonalcoholic fatty liver disease: a randomized controlled clinical trial","volume":"148","author":"Bakhshimoghaddam","year":"2018","journal-title":"J Nutr"},{"key":"ref43","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12876-020-01194-2","article-title":"Fructo-oligosaccharides ameliorate steatohepatitis, visceral adiposity, and associated chronic inflammation via increased production of short-chain fatty acids in a mouse model of non-alcoholic steatohepatitis","volume":"20","author":"Takai","year":"2020","journal-title":"BMC Gastroenterol"},{"key":"ref44","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1093\/aje\/kwx061","article-title":"Agreement between 35 published frailty scores in the general population","volume":"186","author":"Aguayo","year":"2017","journal-title":"Am J Epidemiol"},{"key":"ref45","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1007\/s13679-020-00379-w","article-title":"Probiotics, prebiotics, Synbiotics, Postbiotics, and obesity: current evidence, controversies, and perspectives","volume":"9","author":"Vallianou","year":"2020","journal-title":"Curr Obes Rep"},{"key":"ref46","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1053\/j.gastro.2020.01.031","article-title":"Synbiotics Alter fecal microbiomes, but not liver fat or fibrosis, in a randomized trial of patients with nonalcoholic fatty liver disease","volume":"158","author":"Scorletti","year":"2020","journal-title":"Gastroenterology"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"3192","DOI":"10.3390\/nu13093192","article-title":"The effect of probiotics (MCP(\u00ae) BCMC(\u00ae) strains) on hepatic steatosis, small intestinal mucosal immune function, and intestinal barrier in patients with non-alcoholic fatty liver disease","volume":"13","author":"Mohamad Nor","year":"2021","journal-title":"Nutrients"},{"key":"ref48","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1186\/s12876-024-03424-3","article-title":"The effect of probiotic supplementation on non-alcoholic fatty liver disease (NAFLD) fibrosis score in patients attending a tertiary hospital clinic in Cairo, Egypt","volume":"24","author":"Abd El Hamid","year":"2024","journal-title":"BMC Gastroenterol"},{"key":"ref49","doi-asserted-by":"publisher","first-page":"1087260","DOI":"10.3389\/fendo.2022.1087260","article-title":"Advancements in the treatment of non-alcoholic fatty liver disease (NAFLD)","volume":"13","author":"Rong","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref50","doi-asserted-by":"publisher","first-page":"116","DOI":"10.14309\/ajg.0000000000000845","article-title":"Effects of statin use on the development and progression of nonalcoholic fatty liver disease: a Nationwide nested case-control study","volume":"116","author":"Lee","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"ref51","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.lfs.2015.02.003","article-title":"Singular effects of PPAR agonists on nonalcoholic fatty liver disease of diet-induced obese mice","volume":"127","author":"Barbosa-da-Silva","year":"2015","journal-title":"Life Sci"},{"key":"ref52","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1080\/13543784.2020.1763302","article-title":"Bile acid modulators for the treatment of nonalcoholic steatohepatitis (NASH)","volume":"29","author":"Fiorucci","year":"2020","journal-title":"Expert Opin Investig Drugs"},{"key":"ref53","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/j.biochi.2016.11.009","article-title":"PPARs and nonalcoholic fatty liver disease","volume":"136","author":"Liss","year":"2017","journal-title":"Biochimie"}],"container-title":["Frontiers in Nutrition"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1686937\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,25]],"date-time":"2025-11-25T13:56:27Z","timestamp":1764078987000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fnut.2025.1686937\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,25]]},"references-count":53,"alternative-id":["10.3389\/fnut.2025.1686937"],"URL":"https:\/\/doi.org\/10.3389\/fnut.2025.1686937","relation":{},"ISSN":["2296-861X"],"issn-type":[{"value":"2296-861X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,25]]},"article-number":"1686937"}}